Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticaria-Reference-Cited by-同舟云学术

Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticaria

Published:2022-02 Issue:2 Volume:12 Page:
ISSN:2045-7022
Container-title:Clinical and Translational Allergy
language:en
Short-container-title:Clinical & Translational All

Author:

Giménez‐Arnau Ana¹^ORCID,Maurer Marcus²^ORCID,Bernstein Jonathan³^ORCID,Staubach Petra⁴,Barbier Nathalie⁵^ORCID,Hua Eva⁶^ORCID,Severin Thomas⁵,Joubert Yolandi⁵,Janocha Reinhold⁵,Balp Maria‐Magdalena⁵

Affiliation:

1. Department of Dermatology Hospital del Mar Institut Mar d´Investigacions Mèdiques Universitat Autònoma Barcelona Spain

2. Department of Dermatology and Allergy Dermatological Allergology Allergie‐Centrum‐Charité Charité ‐ Universitätsmedizin Berlin Berlin Germany

3. Bernstein Allergy Group and Bernstein Clinical Research Center College of Medicine Cincinnati Ohio USA

4. Department of Dermatology University Medical Center Mainz Mainz Germany

5. Novartis Pharma AG Basel Switzerland

6. China Novartis Institutes for Biomedical Research Co. Ltd Shanghai China

Publisher

Wiley

Subject

Immunology and Allergy,Immunology,Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/clt2.12121

Reference28 articles.

1. ASSURE‐CSU: a real‐world study of burden of disease in patients with symptomatic chronic spontaneous urticaria

2. ATTENTUS, a German online survey of patients with chronic urticaria highlighting the burden of disease, unmet needs and real-life clinical practice

3. The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU

4. The global burden of chronic urticaria for the patient and society*

5. Characteristics and determinants of patient burden and needs in the treatment of chronic spontaneous urticaria

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality of life measurement in assessing treatment effectiveness in urticaria: European experts position statement;International Journal of Dermatology;2024-07-04

2. Non–Skin Related Symptoms Are Common in Chronic Spontaneous Urticaria and Linked to Active and Uncontrolled Disease: Results From the Chronic Urticaria Registry;The Journal of Allergy and Clinical Immunology: In Practice;2024-07

3. Quality of life measurement in urticaria: Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient‐Oriented Outcomes and Urticaria and Angioedema;Journal of the European Academy of Dermatology and Venereology;2024-06-10

4. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials;The Lancet;2024-01

5. CRUSE^®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria;Clinical and Translational Allergy;2024-01